Table 2 Background characteristics of patients by bleeding status on antithrombotic group
|  | Bleeding (n = 21) | Non-bleeding (n = 69) | p value | |
|---|---|---|---|---|
Age(yr) | 65.4 ± 13.4 | 64.7 ± 13.8 | 0.838 | |
Gender (M/F)(%M) | 12/9(57.1) | 42/27(60.9) | 0.760 | |
H. pylori infection(+/−)(%positive) | 17/4(81.0) | 56/13(81.2) | 0.983 | |
Tumor size(mm) | 15.8 ± 6.1 | 15.7 ± 5.4 | 0.942 | |
Tumor type | IIa | 11 | 40 | 0.411 |
IIa + IIc | 2 | 12 | ||
IIc | 8 | 17 | ||
Ulcerative scars in the tumor(+/−)(%positive) | 5/16(23.8) | 16/53(23.2) | 0.953 | |
Histology (Adenoma/Well-differentiated adenocarcinoma) | 3/18(14.3) | 9/60(13.0) | 0.883 | |
Duaration of ESD(min) | 50.3 ± 18.8 | 42.1 ± 14.9 | 0.014※ | |
Location of tumor | Antrum | 9 | 32 | 0.528 |
Angulus | 7 | 15 | ||
Corpus | 5 | 22 | ||
Concrurrent disease(diabetes, renal failure, cirrhosis)(+/−)(%positive) | 3/18(14.3) | 25/44(36.2) | 0.057 | |
Gastroprotective agent(+/−)(%positive) | 5/16(23.8) | 34/35(49.3) | 0.039※ | |
LDA + warfarin(+/−)(%positive) | 12/9(57.1) | 9/60(13.0) | <0.001※ | |
LDA + thienopyridine(+/−)(%positive) | 3/18(14.3) | 20/49(29.0) | 0.176 | |